openPR Logo
Press release

Community-Acquired Bacterial Pneumonia (CABP) Market is expected to reach USD 14.2 billion by 2034

09-10-2025 12:41 PM CET | Health & Medicine

Press release from: Exactitude Consultancy

Community-Acquired Bacterial Pneumonia

Community-Acquired Bacterial Pneumonia

Community-acquired bacterial pneumonia (CABP) is a serious lung infection contracted outside hospital or healthcare settings, most commonly caused by Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, and other bacterial pathogens. It remains a leading cause of morbidity, mortality, and healthcare costs worldwide, particularly among children, elderly populations, and immunocompromised patients.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71735

The CABP market is driven by rising incidence, antimicrobial resistance (AMR), approvals of novel antibiotics, rapid diagnostics, and global vaccination efforts. With a growing pipeline of next-generation antibiotics and improved clinical guidelines, the CABP market is expected to witness significant expansion over the next decade.

Market Overview
• Market Size (2024): USD 8.7 billion
• Forecast (2034): USD 14.2 billion
• CAGR (2025-2034): 5.0%

The CABP market is expanding as new drugs enter the market, diagnostics evolve, and global immunization programs reduce disease severity but sustain demand for effective treatment.

Key Highlights:
• CABP remains one of the top infectious causes of death globally.
• New antibiotic approvals (e.g., lefamulin, omadacycline) provide options for resistant pathogens.
• Pneumococcal vaccination programs reducing incidence, especially in children.
• Growing role of molecular diagnostics for early pathogen identification.

Segmentation Analysis
By Product Type:
• Antibiotics
o Macrolides (Azithromycin, Clarithromycin)
o Beta-Lactams (Amoxicillin, Ceftriaxone, Ceftaroline)
o Fluoroquinolones (Levofloxacin, Moxifloxacin)
o Tetracyclines (Omadacycline, Doxycycline)
o Pleuromutilins (Lefamulin)
• Combination Therapies
o Beta-lactam + Macrolide Regimens
• Diagnostics
o Molecular PCR-Based Tests
o Rapid Antigen Tests
o Culture-Based Testing
• Vaccines
o Pneumococcal Vaccines (PCV13, PCV15, PCV20, PPSV23)
o Other Bacterial Vaccines

By Platform:
• Small Molecule Antibiotics
• Biologics (vaccines)
• Diagnostic Platforms

By Technology:
• Rapid Molecular Diagnostics (PCR, NAATs)
• Next-Gen Sequencing for Resistance Profiles
• AI-Based Imaging & Predictive Diagnostics

By End Use:
• Hospitals
• Outpatient Clinics
• Diagnostic Laboratories
• Home Care (oral therapies)

By Application:
• Adult CABP
• Pediatric CABP
• Immunocompromised Patient CABP
• Clinical Research

Segmentation Summary:
Antibiotics dominate treatment, but vaccines play a major preventive role, while diagnostics are crucial for guiding therapy in resistant cases. Hospitals remain the largest end users, though outpatient and home therapies are growing.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71735/community-acquired-bacterial-pneumonia-market

Regional Analysis
North America
• Largest market with ~38% share in 2024.
• High CABP prevalence in elderly populations.
• FDA approvals of novel antibiotics boosting adoption.
Europe
• Holds ~28% share.
• Germany, UK, and France leading in pneumococcal vaccination coverage.
• Strong antimicrobial stewardship programs guiding CABP therapy.
Asia-Pacific
• Fastest-growing region with CAGR of ~6.3%.
• High CABP burden in India, China, and Southeast Asia.
• Rising healthcare investments and expanded vaccination programs.
Middle East & Africa
• High disease burden but limited access to advanced antibiotics.
• Gradual improvements in tertiary hospital care.
Latin America
• Brazil and Mexico drive regional demand.
• Expanding immunization programs and diagnostic adoption.
Regional Summary:
North America and Europe dominate today due to strong infrastructure and new drug launches, while Asia-Pacific grows fastest due to high incidence and expanding access.

Market Dynamics
Key Growth Drivers:
• Rising global prevalence of CABP, especially in aging populations.
• Strong pipeline of novel antibiotics (lefamulin, omadacycline).
• Expanded pneumococcal vaccination programs reducing mortality.
• Growing adoption of molecular diagnostics for faster treatment decisions.

Key Challenges:
• Antimicrobial resistance limiting effectiveness of older antibiotics.
• High costs of newer antibiotics compared to generics.
• Limited awareness and access in low-income regions.
• Risk of inappropriate antibiotic prescribing.

Latest Trends:
• Long-acting antibiotics reducing hospital stays.
• AI-driven chest imaging for pneumonia diagnosis.
• Development of next-gen pneumococcal vaccines with broader coverage.
• Public-private partnerships to address AMR (WHO, BARDA, CARB-X).

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71735

Competitor Analysis
Major Players in the Market:
• Pfizer Inc. (Prevnar family of vaccines)
• Merck & Co., Inc. (Pneumovax 23, Vaxneuvance)
• Nabriva Therapeutics (Lefamulin)
• Paratek Pharmaceuticals (Omadacycline)
• Johnson & Johnson
• GlaxoSmithKline plc
• Novartis AG
• Sanofi S.A.
• Abbott Laboratories (diagnostics)
• Roche Diagnostics

Competitive Summary:
Pfizer and Merck dominate the vaccine space, while Nabriva and Paratek are leading innovators in next-gen antibiotics. Abbott and Roche lead diagnostics, while J&J, GSK, and Novartis maintain strong antibiotic portfolios. Competition focuses on resistant pathogen coverage, vaccine expansion, and diagnostic speed.

Conclusion
The Community-Acquired Bacterial Pneumonia (CABP) Market, valued at USD 8.7 billion in 2024, is projected to reach USD 14.2 billion by 2034, growing at a CAGR of 5.0%. Rising prevalence, antibiotic innovation, vaccination programs, and diagnostics are shaping the future of CABP management.

Key Takeaways:
• Antibiotics remain the backbone of CABP therapy, but new drug approvals strengthen options.
• Vaccination plays a critical preventive role.
• North America and Europe lead, while Asia-Pacific grows fastest.
• AI diagnostics and next-gen vaccines will transform future care.

The next decade will see CABP management evolve toward faster diagnostics, precision antibiotic use, and stronger preventive vaccination strategies, creating significant opportunities for pharmaceutical, diagnostic, and vaccine innovators.

This report is also available in the following languages : Japanese (市中感染性細菌性肺炎市場), Korean (지역사회 감염성 세균성 폐렴 시장), Chinese (社区获得性细菌性肺炎市场), French (Marché de la pneumonie bactérienne acquise dans la communauté), German (Markt für ambulant erworbene bakterielle Lungenentzündung), and Italian (Mercato della polmonite batterica acquisita in comunità), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71735/community-acquired-bacterial-pneumonia-market#request-a-sample

Our More Reports:
Glaucoma Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72297/glaucoma-patient-pool-analysis-market

Neurotrophic Keratitis Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72298/neurotrophic-keratitis-patient-pool-analysis-market

Retinitis Pigmentosa Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72299/retinitis-pigmentosa-patient-pool-analysis-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Community-Acquired Bacterial Pneumonia (CABP) Market is expected to reach USD 14.2 billion by 2034 here

News-ID: 4177426 • Views:

More Releases from Exactitude Consultancy

Vacuum Insulated Pipe Market Projected to Reach USD 2.36 Billion by 2034
Vacuum Insulated Pipe Market Projected to Reach USD 2.36 Billion by 2034
Introduction: A Market Built on Cryogenic Efficiency and Innovation The global Vacuum Insulated Pipe (VIP) market is witnessing a steady surge driven by the expanding cryogenic industry, increased liquefied natural gas (LNG) trade, and rising demand for efficient liquid gas transportation systems. These specialized double-wall pipes, engineered with high vacuum insulation between inner and outer layers, have become indispensable in industries handling cryogenic fluids such as liquid nitrogen, oxygen, argon, and
Solar PV Mounting Systems Market is Expected to Reach USD 31.7 Billion by 2034
Solar PV Mounting Systems Market is Expected to Reach USD 31.7 Billion by 2034
Introduction: Powering the Next Decade of Solar Expansion The Solar PV Mounting Systems Market is emerging as a crucial pillar in the clean energy revolution, enabling efficient, cost-effective, and durable installations of photovoltaic (PV) modules across rooftops, open fields, and floating structures. As the world accelerates toward carbon neutrality, the demand for robust, modular, and adaptable mounting systems has intensified across residential, commercial, and utility-scale solar projects. Download Full PDF Sample Copy
Tall Oil Fatty Acid Market projected to reach USD 2.21 billion by 2034
Tall Oil Fatty Acid Market projected to reach USD 2.21 billion by 2034
Introduction: A Sustainable Feedstock Powering the Future of Bio-based Chemicals The Tall Oil Fatty Acid (TOFA) Market is gaining strong traction as industries increasingly shift toward renewable, sustainable, and bio-based chemical alternatives. Derived as a byproduct from the kraft pulping process of pine wood, TOFA has become a vital raw material in the production of alkyd resins, dimer acids, lubricants, coatings, and adhesives. Its unique composition-rich in oleic and linoleic acids-makes
Lithium-Ion Battery Recycling Market Projected to Reach USD 27.3 Billion by 2034
Lithium-Ion Battery Recycling Market Projected to Reach USD 27.3 Billion by 2034
Introduction: Powering the Circular Energy Transition As the world accelerates toward electrification and clean energy, the demand for lithium-ion batteries has skyrocketed-fueling everything from electric vehicles (EVs) to smartphones and grid storage systems. However, this exponential growth brings with it an urgent environmental challenge: how to sustainably manage end-of-life batteries. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/25354 The Lithium-Ion Battery Recycling Market has emerged as a cornerstone of the global

All 5 Releases


More Releases for CABP

Community-Acquired Bacterial Pneumonia (CABP) Market Growth, Applications, Innov …
Introduction Community-acquired bacterial pneumonia (CABP) remains one of the most significant infectious diseases globally, particularly among the elderly, immunocompromised patients, and individuals with chronic comorbidities. Caused primarily by Streptococcus pneumoniae, CABP accounts for millions of hospitalizations each year, posing a substantial healthcare and economic burden. With the rise of antibiotic resistance, aging populations, and post-viral pneumonia cases, demand for effective treatments and preventive strategies is increasing. The CABP Market is undergoing transformation
Community-Acquired Bacterial Pneumonia (CABP) Pipeline Analysis 2025: EMA, PDMA, …
(Albany, United States) "Community-Acquired Bacterial Pneumonia (CABP) Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Community-Acquired Bacterial Pneumonia (CABP) Market. As per DelveInsight's assessment, globally, Community-Acquired Bacterial Pneumonia (CABP) pipeline constitutes of key companies continuously working towards developing Community-Acquired Bacterial Pneumonia (CABP) treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The
From Bench to Bedside: Optimizing Treatment Pathways for Community-acquired Bact …
The "Community-acquired Bacterial Pneumonia  (CABP) Treatment Market was valued for $6.5 billion in 2024 and is estimated to reach $18.5 billion by 2031, exhibiting a CAGR of 11.2% from 2024 to 2031. Coherent Market Insights has released a statistical report titled "Community-acquired Bacterial Pneumonia  (CABP) Treatment Market Recent Trends, In-depth Analysis, Size, and Forecast 2024-2031." This report offers a comprehensive overview of the competitive landscape, geographical segmentation, innovation, future
Community-Acquired Bacterial Pneumonia (CABP) Market to Register Incremental Gro …
DelveInsight's "Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Community-Acquired Bacterial Pneumonia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Community-Acquired Bacterial Pneumonia
Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market to Overall …
The global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs market size was valued at $ 1,269.73 Mn in 2020, and is projected to reach $ 2,075.34 Mn by 2027, registering a CAGR of 7.5% from 2020 to 2027. Coherent Market Insights added new research on Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market- Opportunity Analysis and Industry Forecast, 2022-2028. The Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs market explores comprehensive study on various
Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Growth in F …
Coherent Market Insights has released a new research study on the "Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market" which aims to provide a thorough examination of the factors influencing global business introduction and outlook. The Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Report detailed information and overview highlight the most recent trends in various regions. Leading market participants will benefit from the trading insights provided in this report. The